Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-11… Read more
Taysha Gene Therapies Inc (TSHA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.110x
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has a cash flow conversion efficiency ratio of -0.110x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.17 Million) by net assets ($218.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taysha Gene Therapies Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Taysha Gene Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Taysha Gene Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taysha Gene Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ CheilJedang Corp
KO:097955
|
0.068x |
|
Genomma Lab Internacional S.A.B. de C.V
PINK:GNMLF
|
0.002x |
|
Business First Bancshares Inc
NASDAQ:BFST
|
0.019x |
|
HBL ENGINEERING LTD
NSE:HBLENGINE
|
N/A |
|
Fujian Qingshan Paper Industry Co Ltd
SHG:600103
|
0.011x |
|
PVR INOX Ltd.
NSE:PVRINOX
|
0.089x |
|
Northeast Bancorp
NASDAQ:NBN
|
0.040x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
Annual Cash Flow Conversion Efficiency for Taysha Gene Therapies Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Taysha Gene Therapies Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.53 Million | $-81.22 Million | -1.136x | -16.55% |
| 2023-12-31 | $74.94 Million | $-73.02 Million | -0.974x | +98.95% |
| 2022-12-31 | $949.00K | $-88.39 Million | -93.140x | -7490.43% |
| 2021-12-31 | $95.38 Million | $-117.04 Million | -1.227x | -903.50% |
| 2020-12-31 | $251.30 Million | $-30.73 Million | -0.122x | +87.77% |
| 2019-12-31 | $-135.00K | $135.00K | -1.000x | -- |